Mizuho analyst Ann Hynes says that given the headwinds in its base business, she now expects a continued low level of acquisition activity for Mednax not just in 2019, but also in 2020. The analyst lowered her 2020 adjusted EBITDA estimate to $505M from $523M, below the consensus at $513M. She also dropped her price target for the shares to $23 from $24 and keeps a Neutral rating on Mednax.
Stocks are having another quiet morning as investors wait for the Federal Reserve to wrap up its last rate setting meeting of the year. There are virtually... To see the rest of the story go to thefly.com. See Story Here